ARZERRA® (Ofatumumab)

The FDA on January 19, 2016 approved ARZERRA® for extended treatment of patients who are in complete or partial response after at least two lines of therapy, for recurrent or progressive Chronic Lymphocytic Leukemia (CLL). ARZERRA® was previously approved for the treatment of previously untreated patients with CLL for whom Fludarabine-based therapy was considered inappropriate and also for patients with CLL refractory to Fludarabine and Alemtuzumab. ARZERRA® is a product of Novartis Pharmaceuticals Corporation.